Supernus Pharmaceuticals (SUPN) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Share on StockTwits

Supernus Pharmaceuticals (NASDAQ:SUPN) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.09, Briefing.com reports. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. The business had revenue of $102.99 million during the quarter, compared to the consensus estimate of $100.75 million. During the same quarter in the prior year, the company posted $0.29 earnings per share. Supernus Pharmaceuticals’s revenue was up 28.1% compared to the same quarter last year.

NASDAQ:SUPN traded up $3.54 during trading on Wednesday, reaching $45.19. The company’s stock had a trading volume of 1,035,656 shares, compared to its average volume of 719,827. The company has a market capitalization of $2.43 billion, a PE ratio of 35.87 and a beta of 0.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54. Supernus Pharmaceuticals has a 12 month low of $34.90 and a 12 month high of $61.25.

A number of large investors have recently made changes to their positions in SUPN. SevenBridge Financial Group LLC bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $113,000. Cubist Systematic Strategies LLC bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $203,000. NumerixS Investment Technologies Inc bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $204,000. Gryphon Financial Partners LLC grew its stake in Supernus Pharmaceuticals by 302.5% in the 3rd quarter. Gryphon Financial Partners LLC now owns 4,037 shares of the specialty pharmaceutical company’s stock valued at $204,000 after purchasing an additional 3,034 shares during the period. Finally, Everence Capital Management Inc. bought a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $205,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Several equities research analysts recently issued reports on SUPN shares. Cantor Fitzgerald reiterated a “buy” rating and set a $56.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 14th. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. Mizuho initiated coverage on Supernus Pharmaceuticals in a research note on Monday, September 17th. They issued a “buy” rating and a $61.00 price objective for the company. Piper Jaffray Companies set a $44.00 price objective on Supernus Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, August 28th. Finally, BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, September 19th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $54.78.

TRADEMARK VIOLATION WARNING: This story was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://macondaily.com/2018/11/07/supernus-pharmaceuticals-supn-announces-quarterly-earnings-results-beats-expectations-by-0-09-eps.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Story: Stop Order

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply